TY - JOUR AU - Chan, K. -. L. AU - Lade, S. AU - Prince, H. M. AU - Harrison, S. J. PY - 2016 DA - 2016// TI - Update and new approaches in the treatment of Castleman disease JO - J Blood Med VL - 7 UR - https://doi.org/10.2147/JBM.S60514 DO - 10.2147/JBM.S60514 ID - Chan2016 ER - TY - JOUR AU - Sopfe, J. AU - Endres, A. AU - Campbell, K. AU - Hayes, K. AU - Trout, A. T. AU - Liang, X. PY - 2019 DA - 2019// TI - Castleman disease in pediatrics: insights on presentation, treatment, and outcomes from a two-site retrospective cohort study JO - Pediatr Blood Cancer VL - 66 UR - https://doi.org/10.1002/pbc.27613 DO - 10.1002/pbc.27613 ID - Sopfe2019 ER - TY - JOUR AU - Yoshizaki, K. AU - Matsuda, T. AU - Nishimoto, N. AU - Kuritani, T. AU - Taeho, L. AU - Aozasa, K. PY - 1989 DA - 1989// TI - Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease JO - Blood VL - 74 UR - https://doi.org/10.1182/blood.V74.4.1360.1360 DO - 10.1182/blood.V74.4.1360.1360 ID - Yoshizaki1989 ER - TY - JOUR AU - Piguet, C. AU - Dubouillé, C. AU - Petit, B. AU - Longis, B. AU - Paseaud, E. AU - Lumley, L. PY - 2004 DA - 2004// TI - Castleman disease in a child JO - Arch Pediatr Organe Off Soc Francaise Pediatr VL - 11 UR - https://doi.org/10.1016/j.arcped.2004.06.035 DO - 10.1016/j.arcped.2004.06.035 ID - Piguet2004 ER - TY - JOUR AU - Galeotti, C. AU - Tran, T. -. A. AU - Franchi-Abella, S. AU - Fabre, M. AU - Pariente, D. AU - Koné-Paut, I. PY - 2008 DA - 2008// TI - IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report JO - J Pediatr Hematol Oncol VL - 30 UR - https://doi.org/10.1097/MPH.0b013e31818ab31f DO - 10.1097/MPH.0b013e31818ab31f ID - Galeotti2008 ER - TY - JOUR AU - Galeotti, C. AU - Boucheron, A. AU - Guillaume, S. AU - Koné-Paut, I. PY - 2012 DA - 2012// TI - Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody JO - Mol Cancer Ther VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-11-0972 DO - 10.1158/1535-7163.MCT-11-0972 ID - Galeotti2012 ER - TY - JOUR AU - Gijn, M. E. AU - Ceccherini, I. AU - Shinar, Y. AU - Carbo, E. C. AU - Slofstra, M. AU - Arostegui, J. I. PY - 2018 DA - 2018// TI - New workflow for classification of genetic variants’ pathogenicity applied to hereditary recurrent fevers by the international study Group for Systemic Autoinflammatory Diseases (INSAID) JO - J Med Genet VL - 55 UR - https://doi.org/10.1136/jmedgenet-2017-105216 DO - 10.1136/jmedgenet-2017-105216 ID - Gijn2018 ER - TY - STD TI - Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017. https://doi.org/10.1182/blood-2016-10-746933. ID - ref8 ER - TY - JOUR AU - Oksenhendler, E. AU - Boutboul, D. AU - Fajgenbaum, D. AU - Mirouse, A. AU - Fieschi, C. AU - Malphettes, M. PY - 2018 DA - 2018// TI - The full spectrum of Castleman disease: 273 patients studied over 20 years JO - Br J Haematol VL - 180 UR - https://doi.org/10.1111/bjh.15019 DO - 10.1111/bjh.15019 ID - Oksenhendler2018 ER - TY - JOUR AU - Hill, A. J. AU - Tirumani, S. H. AU - Rosenthal, M. H. AU - Shinagare, A. B. AU - Carrasco, R. D. AU - Munshi, N. C. PY - 2015 DA - 2015// TI - Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients JO - Br J Radiol VL - 88 UR - https://doi.org/10.1259/bjr.20140670 DO - 10.1259/bjr.20140670 ID - Hill2015 ER - TY - JOUR AU - Liu, A. Y. AU - Nabel, C. S. AU - Finkelman, B. S. AU - Ruth, J. R. AU - Kurzrock, R. AU - Rhee, F. PY - 2016 DA - 2016// TI - Idiopathic multicentric Castleman’s disease: a systematic literature review JO - Lancet Haematol VL - 3 UR - https://doi.org/10.1016/S2352-3026(16)00006-5 DO - 10.1016/S2352-3026(16)00006-5 ID - Liu2016 ER - TY - JOUR AU - Rassouli, N. AU - Obmann, V. C. AU - Sandhaus, L. M. AU - Herrmann, K. A. PY - 2018 DA - 2018// TI - (18F)-FDG-PET/MRI of unicentric retroperitoneal Castleman disease in a pediatric patient JO - Clin Imaging VL - 50 UR - https://doi.org/10.1016/j.clinimag.2018.03.010 DO - 10.1016/j.clinimag.2018.03.010 ID - Rassouli2018 ER - TY - JOUR AU - Leroy, S. AU - Moshous, D. AU - Cassar, O. AU - Reguerre, Y. AU - Byun, M. AU - Pedergnana, V. PY - 2012 DA - 2012// TI - Multicentric Castleman disease in an HHV8-infected child born to consanguineous parents with systematic review JO - Pediatrics VL - 129 UR - https://doi.org/10.1542/peds.2010-2739 DO - 10.1542/peds.2010-2739 ID - Leroy2012 ER - TY - STD TI - Van Nieuwenhove E, Humblet-Baron S, Van Eyck L, De Somer L, Dooley J, Tousseyn T, et al. ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease. Pediatrics. 2018;142(3). https://doi.org/10.1542/peds.2017-2266. ID - ref14 ER - TY - STD TI - Boutboul D, Fadlallah J, Chawki S, Fieschi C, Malphettes M, Dossier A, et al. Treatment and outcome of Unicentric Castleman disease: a retrospective analysis of 71 cases. Br J Haematol. 2019. https://doi.org/10.1111/bjh.15921. ID - ref15 ER - TY - STD TI - Talat N, Belgaumkar AP, Schulte K-M. Surgery in Castleman’s disease: a systematic review of 404 published cases. Ann Surg. 2012;255(4):677–84. https://doi.org/10.1097/SLA.0b013e318249dcdc. ID - ref16 ER - TY - JOUR AU - Rhee, F. AU - Wong, R. S. AU - Munshi, N. AU - Rossi, J. -. F. AU - Ke, X. -. Y. AU - Fosså, A. PY - 2014 DA - 2014// TI - Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70319-5 DO - 10.1016/S1470-2045(14)70319-5 ID - Rhee2014 ER - TY - STD TI - van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115–24. https://doi.org/10.1182/blood-2018-07-862334. ID - ref18 ER - TY - STD TI - Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–32. https://doi.org/10.1182/blood-2004-12-4602. ID - ref19 ER - TY - STD TI - Turcotte LM, Correll CK, Reed RC, Moertel CL. Sustained remission of severe multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance. Pediatr Blood Cancer. 2014;61(4):737–9. https://doi.org/10.1002/pbc.24761. ID - ref20 ER - TY - STD TI - Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, et al. The clinical spectrum of Castleman’s disease. Am J Hematol. 2012;87(11):997–1002. https://doi.org/10.1002/ajh.23291. ID - ref21 ER -